Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma

@article{Ouellet2016PopulationPA,
  title={Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma},
  author={Daniele Ouellet and Nastya Kassir and Joannellyn Chiu and Mohamad-Samer Mouksassi and Cathrine Leonowens and Donna Hardy Cox and Douglas J Demarini and O. D. Danielle Gardner and Wendy A Crist and Kiran Mahendrabhai Patel},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2016},
  volume={77},
  pages={807-817}
}
AbstractPurpose To characterize the pharmacokinetics of oral trametinib, a first in class MEK inhibitor, identify covariates, and describe the relationship between exposure and clinical effects in patients with BRAF V600 metastatic melanoma.Experimental designTrametinib concentrations obtained in three clinical studies were included in the population pharmacokinetic analysis. Trametinib 2 mg once daily was administered in the Phase 2 and 3 studies. The impact of exposure [trough (Cmin) or… CONTINUE READING
BETA
1
Twitter Mention

Citations

Publications citing this paper.
SHOWING 1-6 OF 6 CITATIONS

Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia

  • Cancer Chemotherapy and Pharmacology
  • 2019
VIEW 11 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

  • Clinical pharmacology and therapeutics
  • 2017
VIEW 4 EXCERPTS
CITES BACKGROUND, RESULTS & METHODS
HIGHLY INFLUENCED

Targeting MEK in a Translational Model of Histiocytic Sarcoma.

  • Molecular cancer therapeutics
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 20 REFERENCES

Evaluation of the effects of food on the single-dose pharmacokinetics of trametinib a first-in-class MEK inhibitor, in patients with cancer

DS Cox, K Papdopoulos, +7 authors D Ouellet
  • J Clin Pharmacol. doi:10.1002/jcph.115
  • 2013
VIEW 1 EXCERPT

A (2011) NONMEM user’s guides. Icon Development Solutions Ellicott City, Maryland

S Beal, LB Sheiner, Boeckmann
  • 2011
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…